Skip to main content
Erschienen in: The Journal of Headache and Pain 1/2014

Open Access 01.12.2014 | Meeting abstract

EHMTI-0326. OnabotulinumtoxinA for the treatment of chronic paroxysmal hemicrania: a case report

verfasst von: D Dolezil

Erschienen in: The Journal of Headache and Pain | Sonderheft 1/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Introduction

Chronic paroxysmal hemicrania (CPH) is characterized by attacks of very severe, unilateral pain, fulfilling criteria of The International Classification of Headache Disorders, 3rd edition, beta version ( ICHD-3 beta) for paroxysmal hemicrania and occurring without a remission period, or with remissions lasting <1 month, for at least 1 year.

Aims

OnabotulinumtoxinA is now used for the treatment of chronic migraine.We wanted to try the treatment of CPH with OnabotulinumtoxinA, because other treatments have not been effective.

Patient and methods

We present the case of a patient diagnosed with CPH that lasts for 32 years. Attacks of headache lasted about 15 years without remission. The patient described her headaches as attacks of hemicrania lasted from 15 to 25 minutes with a frequency usually 8 times per day. OnabotulinumtoxinA was infiltrated at eight ipsilateral points. Total dose was 45 units (each intramuscular injection site was 0.1 mL = 5 U onabotulinumtoxinA). Seven points were identical as in the treatment of chronic migraine in the frontal and temporal areas and one point was in infraorbital area.Method applications of onabotulinumtoxinA based on the methodology of application of onabotulinumtoxinA in patients with chronic migraine.

Results

The CPH showed a dramatic response to onabotulinumtoxinA infiltration. Effect of treatment was evident as early as three weeks after the first injection, gradually improved, it takes seven months from start of treatment with 3-monthly infiltrations.

Conclusions

The treatment of CPH with OnabotulinumtoxinA significantly improved the quality of life of the patient.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://​creativecommons.​org/​licenses/​by/​4.​0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Metadaten
Titel
EHMTI-0326. OnabotulinumtoxinA for the treatment of chronic paroxysmal hemicrania: a case report
verfasst von
D Dolezil
Publikationsdatum
01.12.2014
Verlag
Springer Milan
Erschienen in
The Journal of Headache and Pain / Ausgabe Sonderheft 1/2014
Print ISSN: 1129-2369
Elektronische ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-15-S1-C16

Weitere Artikel der Sonderheft 1/2014

The Journal of Headache and Pain 1/2014 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.